Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2018 Authors' conclusions Overall, abemaciclib with endocrine therapy substantially reduces the risk of disease progression and increases ORR versus ET alone as initial therapy for HR-positive, HER2-negative ABC in postmenopausal women. OS and QoL data are needed to confirm that patients achieve a clinically relevant benefit over time in the context of increasing toxicity. Biomarker trials that track cellular proliferation and evaluate Rb protein and ER activity may help to identify which patients benefit most from adding abemaciclib as initial treatment. As there are no comparative trials, differences in the safety profiles of CDK4/6 inhibitors may assist physicians in selecting the most appropriate CDK4/6 inhibitor to meet individual patient needs. Indexing Status Subject indexing assigned by CRD MeSH Aminopyridines; Aromatase Inhibitors; Benzimidazoles; Breast; Breast Neoplasms; Humans Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32018000202 Date abstract record published 16/04/2018 |